JP2016526531A - B型アデノウイルスのための投与計画および製剤 - Google Patents
B型アデノウイルスのための投与計画および製剤 Download PDFInfo
- Publication number
- JP2016526531A JP2016526531A JP2016518498A JP2016518498A JP2016526531A JP 2016526531 A JP2016526531 A JP 2016526531A JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016526531 A JP2016526531 A JP 2016526531A
- Authority
- JP
- Japan
- Prior art keywords
- dose
- virus
- administered
- cancer
- coload1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 120
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000009472 formulation Methods 0.000 title claims abstract description 70
- 241000700605 Viruses Species 0.000 claims abstract description 206
- 238000011282 treatment Methods 0.000 claims abstract description 159
- 239000002245 particle Substances 0.000 claims abstract description 115
- 230000000174 oncolytic effect Effects 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 60
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000002648 combination therapy Methods 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 235
- 201000011510 cancer Diseases 0.000 claims description 132
- 230000003612 virological effect Effects 0.000 claims description 90
- 102000004127 Cytokines Human genes 0.000 claims description 42
- 108090000695 Cytokines Proteins 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 38
- 238000001990 intravenous administration Methods 0.000 claims description 34
- 206010033128 Ovarian cancer Diseases 0.000 claims description 27
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- 229940127089 cytotoxic agent Drugs 0.000 claims description 19
- 238000011287 therapeutic dose Methods 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 16
- 238000002560 therapeutic procedure Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 11
- 230000029812 viral genome replication Effects 0.000 claims description 11
- 108700019146 Transgenes Proteins 0.000 claims description 9
- 150000003431 steroids Chemical class 0.000 claims description 9
- 238000001959 radiotherapy Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000036470 plasma concentration Effects 0.000 claims description 7
- 230000003474 anti-emetic effect Effects 0.000 claims description 5
- 229940125683 antiemetic agent Drugs 0.000 claims description 5
- 239000002111 antiemetic agent Substances 0.000 claims description 5
- 239000002221 antipyretic Substances 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 229940125716 antipyretic agent Drugs 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 99
- -1 briji® Chemical compound 0.000 description 49
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 44
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- 238000001802 infusion Methods 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 27
- 206010027476 Metastases Diseases 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 238000002347 injection Methods 0.000 description 25
- 230000002601 intratumoral effect Effects 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 22
- 210000001672 ovary Anatomy 0.000 description 21
- 230000010076 replication Effects 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 20
- 230000002411 adverse Effects 0.000 description 19
- 210000001865 kupffer cell Anatomy 0.000 description 19
- 244000309459 oncolytic virus Species 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 18
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 241001135569 Human adenovirus 5 Species 0.000 description 16
- 230000009401 metastasis Effects 0.000 description 16
- 206010061289 metastatic neoplasm Diseases 0.000 description 16
- 230000001394 metastastic effect Effects 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000001988 toxicity Effects 0.000 description 13
- 231100000419 toxicity Toxicity 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 12
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 12
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 11
- 102100039373 Membrane cofactor protein Human genes 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000012758 nuclear staining Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 210000002845 virion Anatomy 0.000 description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 201000005112 urinary bladder cancer Diseases 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000007416 antiviral immune response Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012385 systemic delivery Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 108010035601 Coxsackie and Adenovirus Receptor Like Membrane Protein Proteins 0.000 description 4
- 102000008198 Coxsackie and Adenovirus Receptor Like Membrane Protein Human genes 0.000 description 4
- 101710091439 Major capsid protein 1 Proteins 0.000 description 4
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000012503 blood component Substances 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000011272 standard treatment Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000003815 abdominal wall Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000004882 non-tumor cell Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 description 3
- SQWZFLMPDUSYGV-POHAHGRESA-N (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=N2)C2=C1 SQWZFLMPDUSYGV-POHAHGRESA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KQDBVHKNIYROHU-UHFFFAOYSA-N 2-[(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2C=N1 KQDBVHKNIYROHU-UHFFFAOYSA-N 0.000 description 2
- IRTDIKMSKMREGO-OAHLLOKOSA-N 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-9-pyrido[1,2-a]pyrimidinyl]ethyl]amino]benzoic acid Chemical compound N([C@H](C)C=1C=2N(C(C=C(N=2)N2CCOCC2)=O)C=C(C)C=1)C1=CC=CC=C1C(O)=O IRTDIKMSKMREGO-OAHLLOKOSA-N 0.000 description 2
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UJIAQDJKSXQLIT-UHFFFAOYSA-N 3-[2,4-diamino-7-(3-hydroxyphenyl)-6-pteridinyl]phenol Chemical compound C=1C=CC(O)=CC=1C1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC(O)=C1 UJIAQDJKSXQLIT-UHFFFAOYSA-N 0.000 description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GNWHRHGTIBRNSM-UHFFFAOYSA-N IC-87114 Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2N=C1 GNWHRHGTIBRNSM-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 description 2
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 241000232901 Nephroma Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101150027249 RL1 gene Proteins 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 108010084938 adenovirus receptor Proteins 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003719 aurora kinase inhibitor Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 229960001785 mirtazapine Drugs 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NRHJQBIYQBAJBZ-UHFFFAOYSA-N n-[4-[2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-4-oxoquinazolin-5-yl]but-3-ynyl]morpholine-4-carboxamide Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC(N(C(=O)C1=2)CC=3C(=CC=CC=3)Cl)=NC1=CC=CC=2C#CCCNC(=O)N1CCOCC1 NRHJQBIYQBAJBZ-UHFFFAOYSA-N 0.000 description 2
- JFVNFXCESCXMBC-UHFFFAOYSA-N n-[5-[4-chloro-3-(2-hydroxyethylsulfamoyl)phenyl]-4-methyl-1,3-thiazol-2-yl]acetamide Chemical compound S1C(=N/C(=O)C)\NC(C)=C1C1=CC=C(Cl)C(S(=O)(=O)NCCO)=C1 JFVNFXCESCXMBC-UHFFFAOYSA-N 0.000 description 2
- 208000025351 nephroma Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229950008461 talimogene laherparepvec Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZVAGBRFUYHSUHA-LZOXOEDVSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C ZVAGBRFUYHSUHA-LZOXOEDVSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- FYCODPVDEFFWSR-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl]urea;methanesulfonic acid Chemical compound CS(O)(=O)=O.N=1C=C(CCN=C2C=3SC=CC=3N=CN2)SC=1NC(O)=NC1=CC=CC(Cl)=C1 FYCODPVDEFFWSR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- QYKHWEFPFAGNEV-UHFFFAOYSA-N 2-[4-[6-chloro-2-[4-(dimethylamino)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(N(C)C)=CC=C1C(NC1=NC=C2Cl)=NC1=C2N1CCN(CC(=O)NC=2SC=CN=2)CC1 QYKHWEFPFAGNEV-UHFFFAOYSA-N 0.000 description 1
- CMRGXVSRHBPJNJ-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=C(F)C(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC=C1Cl CMRGXVSRHBPJNJ-UHFFFAOYSA-N 0.000 description 1
- DNUSLLSECCYLAU-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-(6-morpholin-4-yl-6-oxohex-1-ynyl)quinazolin-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC(N(C(=O)C1=2)CC=3C(=CC=CC=3)Cl)=NC1=CC=CC=2C#CCCCC(=O)N1CCOCC1 DNUSLLSECCYLAU-UHFFFAOYSA-N 0.000 description 1
- AONITTJLFLDVOT-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-[3-(2-methoxyethoxy)prop-1-ynyl]quinazolin-4-one Chemical compound C=1C=CC=C(Cl)C=1CN1C(=O)C=2C(C#CCOCCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=CC(O)=C1 AONITTJLFLDVOT-UHFFFAOYSA-N 0.000 description 1
- XATOQOXZNMLDIC-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-[6-[3-(dimethylamino)pyrrolidin-1-yl]-6-oxohex-1-ynyl]quinazolin-4-one Chemical compound C1C(N(C)C)CCN1C(=O)CCCC#CC1=CC=CC2=C1C(=O)N(CC=1C(=CC=CC=1)Cl)C(CN1C3=NC=NC(N)=C3C(C=3C=C(O)C=CC=3)=N1)=N2 XATOQOXZNMLDIC-UHFFFAOYSA-N 0.000 description 1
- KKFFLLPTNWZVPK-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-fluorophenyl)methyl]-5-[3-[2-(2-methoxyethoxy)ethoxy]prop-1-ynyl]quinazolin-4-one Chemical compound C=1C=CC=C(F)C=1CN1C(=O)C=2C(C#CCOCCOCCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=CC(O)=C1 KKFFLLPTNWZVPK-UHFFFAOYSA-N 0.000 description 1
- ODGUATJPXSLVMA-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(3-chlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC(Cl)=C1 ODGUATJPXSLVMA-UHFFFAOYSA-N 0.000 description 1
- IUWJCOTVUGFZTA-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(4-chlorophenyl)methyl]-5-(3-methoxyprop-1-ynyl)quinazolin-4-one Chemical compound C=1C=C(Cl)C=CC=1CN1C(=O)C=2C(C#CCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=CC(O)=C1 IUWJCOTVUGFZTA-UHFFFAOYSA-N 0.000 description 1
- HUYJOCXOVRKEIW-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[(3-methylsulfonylphenyl)methyl]quinazolin-4-one Chemical compound CS(=O)(=O)C1=CC=CC(CN2C(C3=C(C#C)C=CC=C3N=C2CN2C3=NC=NC(N)=C3C(C=3C=C(O)C=CC=3)=N2)=O)=C1 HUYJOCXOVRKEIW-UHFFFAOYSA-N 0.000 description 1
- OTCDLPGOEYPRQV-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[(4-methylsulfonylphenyl)methyl]quinazolin-4-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CN1C(=O)C2=C(C#C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2C(C=2C=C(O)C=CC=2)=N1 OTCDLPGOEYPRQV-UHFFFAOYSA-N 0.000 description 1
- MVSVRQJROSZUBJ-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[[3-(trifluoromethyl)phenyl]methyl]quinazolin-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC(C(F)(F)F)=C1 MVSVRQJROSZUBJ-UHFFFAOYSA-N 0.000 description 1
- XJGAJHPRETZYHH-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[[4-(trifluoromethyl)phenyl]methyl]quinazolin-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=C(C(F)(F)F)C=C1 XJGAJHPRETZYHH-UHFFFAOYSA-N 0.000 description 1
- RTLSICZZXIACFX-UHFFFAOYSA-N 2-[[4-amino-3-(4-fluoro-3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=C(O)C(F)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC=C1Cl RTLSICZZXIACFX-UHFFFAOYSA-N 0.000 description 1
- PTTGIRJMNMETGF-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxy-3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-(6-morpholin-4-yl-6-oxohex-1-ynyl)quinazolin-4-one Chemical compound C1=C(O)C(OC)=CC(C=2C3=C(N)N=CN=C3N(CC=3N(C(=O)C4=C(C#CCCCC(=O)N5CCOCC5)C=CC=C4N=3)CC=3C(=CC=CC=3)Cl)N=2)=C1 PTTGIRJMNMETGF-UHFFFAOYSA-N 0.000 description 1
- SUUZMEMRUDWAMK-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2,6-difluorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=C(F)C=CC=C1F SUUZMEMRUDWAMK-UHFFFAOYSA-N 0.000 description 1
- FDUASEWUQUUQIV-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-(3-cyclopentylprop-1-ynyl)quinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC(N(C(=O)C1=2)CC=3C(=CC=CC=3)Cl)=NC1=CC=CC=2C#CCC1CCCC1 FDUASEWUQUUQIV-UHFFFAOYSA-N 0.000 description 1
- XZLPIOCVALKFBZ-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-[6-(4-methyl-1,4-diazepan-1-yl)-6-oxohex-1-ynyl]quinazolin-4-one Chemical compound C1CN(C)CCCN1C(=O)CCCC#CC1=CC=CC2=C1C(=O)N(CC=1C(=CC=CC=1)Cl)C(CN1C3=NC=NC(N)=C3C(C=3C=CC(O)=CC=3)=N1)=N2 XZLPIOCVALKFBZ-UHFFFAOYSA-N 0.000 description 1
- ORTOQALNRIMPBF-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-[6-[3-(dimethylamino)pyrrolidin-1-yl]-6-oxohex-1-ynyl]quinazolin-4-one Chemical compound C1C(N(C)C)CCN1C(=O)CCCC#CC1=CC=CC2=C1C(=O)N(CC=1C(=CC=CC=1)Cl)C(CN1C3=NC=NC(N)=C3C(C=3C=CC(O)=CC=3)=N1)=N2 ORTOQALNRIMPBF-UHFFFAOYSA-N 0.000 description 1
- OMVAPOKEPFCGEF-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-[6-[4-(2-methoxyethyl)piperazin-1-yl]-6-oxohex-1-ynyl]quinazolin-4-one Chemical compound C1CN(CCOC)CCN1C(=O)CCCC#CC1=CC=CC2=C1C(=O)N(CC=1C(=CC=CC=1)Cl)C(CN1C3=NC=NC(N)=C3C(C=3C=CC(O)=CC=3)=N1)=N2 OMVAPOKEPFCGEF-UHFFFAOYSA-N 0.000 description 1
- DENSYDWNLNJEQR-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC=C1Cl DENSYDWNLNJEQR-UHFFFAOYSA-N 0.000 description 1
- UVULXADMHSSQFC-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(3,4-dichlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=C(Cl)C(Cl)=C1 UVULXADMHSSQFC-UHFFFAOYSA-N 0.000 description 1
- ALEMKYQPUYKWDY-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(3-chlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC(Cl)=C1 ALEMKYQPUYKWDY-UHFFFAOYSA-N 0.000 description 1
- ANTOVNWJHMCCOO-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(3-methoxyphenyl)methyl]-5-(3-methoxyprop-1-ynyl)quinazolin-4-one Chemical compound C=1C=CC(OC)=CC=1CN1C(=O)C=2C(C#CCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=C(O)C=C1 ANTOVNWJHMCCOO-UHFFFAOYSA-N 0.000 description 1
- ZMQNQPZQOPWFCX-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(4-chloro-2-fluorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=C(Cl)C=C1F ZMQNQPZQOPWFCX-UHFFFAOYSA-N 0.000 description 1
- XIGSLUIZTRLSRB-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(4-chlorophenyl)methyl]-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=C(Cl)C=C1 XIGSLUIZTRLSRB-UHFFFAOYSA-N 0.000 description 1
- ZTFKDFSMPRZEIS-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-benzyl-5-ethynylquinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC=C1 ZTFKDFSMPRZEIS-UHFFFAOYSA-N 0.000 description 1
- ZLSDYPZEGQPHCJ-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-[5-[bis(2-methoxyethyl)amino]pent-1-ynyl]-3-[(2-chlorophenyl)methyl]quinazolin-4-one Chemical compound C=1C=CC=C(Cl)C=1CN1C(=O)C=2C(C#CCCCN(CCOC)CCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=C(O)C=C1 ZLSDYPZEGQPHCJ-UHFFFAOYSA-N 0.000 description 1
- PNUHFWYRJGONAZ-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[(2-fluoro-5-methoxyphenyl)methyl]quinazolin-4-one Chemical compound COC1=CC=C(F)C(CN2C(C3=C(C#C)C=CC=C3N=C2CN2C3=NC=NC(N)=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 PNUHFWYRJGONAZ-UHFFFAOYSA-N 0.000 description 1
- JZGHEKRTCCGWQA-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[(2-fluorophenyl)methyl]quinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC=C1F JZGHEKRTCCGWQA-UHFFFAOYSA-N 0.000 description 1
- POQBZRJCKHPFHP-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[(3-methoxyphenyl)methyl]quinazolin-4-one Chemical compound COC1=CC=CC(CN2C(C3=C(C#C)C=CC=C3N=C2CN2C3=NC=NC(N)=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 POQBZRJCKHPFHP-UHFFFAOYSA-N 0.000 description 1
- CVJWUNOFWLMXGY-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[(4-methylsulfonylphenyl)methyl]quinazolin-4-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CN1C(=O)C2=C(C#C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2C(C=2C=CC(O)=CC=2)=N1 CVJWUNOFWLMXGY-UHFFFAOYSA-N 0.000 description 1
- WKSBDNHHEHXNMM-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[[3-(trifluoromethyl)phenyl]methyl]quinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC(C(F)(F)F)=C1 WKSBDNHHEHXNMM-UHFFFAOYSA-N 0.000 description 1
- MSOXMABFRIRTIK-UHFFFAOYSA-N 2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-3-[[4-(trifluoromethyl)phenyl]methyl]quinazolin-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=C(C(F)(F)F)C=C1 MSOXMABFRIRTIK-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WGPXKFOFEXJMBD-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O WGPXKFOFEXJMBD-UHFFFAOYSA-N 0.000 description 1
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 1
- INEFQSAZKFSDNE-UHFFFAOYSA-N 3-[[2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-4-oxoquinazolin-3-yl]methyl]benzonitrile Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=CC(C#N)=C1 INEFQSAZKFSDNE-UHFFFAOYSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- FAEKTNGTNFHFRB-UHFFFAOYSA-N 4-[[2-[[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-ethynyl-4-oxoquinazolin-3-yl]methyl]benzonitrile Chemical compound N1=C(C=2C=CC(O)=CC=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC(C#C)=C2C(=O)N1CC1=CC=C(C#N)C=C1 FAEKTNGTNFHFRB-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 description 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 241000251204 Chimaeridae Species 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000709698 Coxsackievirus A21 Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010059284 Epidermal necrosis Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000014061 Extranodal Extension Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- RFSMUFRPPYDYRD-CALCHBBNSA-N Ku-0063794 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3C[C@@H](C)O[C@@H](C)C3)N3CCOCC3)C2=N1 RFSMUFRPPYDYRD-CALCHBBNSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
- PQAPVTKIEGUPRN-UHFFFAOYSA-N N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide Chemical compound CC(C)C1=CC=CC=C1CC1=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=CC=2)C(C)(C)C)=C(O)C(O)=C1O PQAPVTKIEGUPRN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010070905 Ovarian cancer stage I Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000003834 Triticum spelta Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- CFQULUVMLGZVAF-OYJDLGDISA-N U0126.EtOH Chemical compound CCO.C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N CFQULUVMLGZVAF-OYJDLGDISA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- OGNYUTNQZVRGMN-UHFFFAOYSA-N ZM447439 Chemical compound N1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 OGNYUTNQZVRGMN-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 229960003687 alizapride Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940005474 atropine / diphenoxylate Drugs 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000012999 benign epithelial neoplasm Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001035 bopindolol Drugs 0.000 description 1
- 229960003166 bromazine Drugs 0.000 description 1
- NUNIWXHYABYXKF-UHFFFAOYSA-N bromazine Chemical compound C=1C=C(Br)C=CC=1C(OCCN(C)C)C1=CC=CC=C1 NUNIWXHYABYXKF-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- PKOMXLRKGNITKG-UHFFFAOYSA-L calcium;hydroxy(methyl)arsinate Chemical compound [Ca+2].C[As](O)([O-])=O.C[As](O)([O-])=O PKOMXLRKGNITKG-UHFFFAOYSA-L 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229950000472 embramine Drugs 0.000 description 1
- URSRSKSNFPUKGH-UHFFFAOYSA-N embramine Chemical compound C=1C=C(Br)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 URSRSKSNFPUKGH-UHFFFAOYSA-N 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- GLDSKRNGVVYJAB-DQSJHHFOSA-N hesperadin Chemical compound C12=CC(NS(=O)(=O)CC)=CC=C2NC(=O)\C1=C(C=1C=CC=CC=1)/NC(C=C1)=CC=C1CN1CCCCC1 GLDSKRNGVVYJAB-DQSJHHFOSA-N 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010151 inverted papilloma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000565 lesser omentum Anatomy 0.000 description 1
- 210000001931 lesser pelvis Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000000271 mature teratoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 208000022951 mixed epithelial stromal tumor Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 208000004707 mucinous cystadenoma Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- OBWNXGOQPLDDPS-UHFFFAOYSA-N n-(2,6-diethylphenyl)-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)N1CC(C(NC(=O)C=2C=CC(=CC=2)N2CCN(C)CC2)=NN2)=C2C1 OBWNXGOQPLDDPS-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960005554 obatoclax mesylate Drugs 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940051877 other opioids in atc Drugs 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 238000011499 palliative surgery Methods 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005547 pelareorep Drugs 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- AIQRJSXKXVZCJO-UHFFFAOYSA-N prop-2-ynoxybenzene Chemical compound C#CCOC1=CC=CC=C1 AIQRJSXKXVZCJO-UHFFFAOYSA-N 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
現在開発中の腫瘍内投与のためのその他の腫瘍溶解性ウイルスは以下である(Sheridan 2013)。
・ Reolysin、腫瘍溶解性レオウイルスの血清型3(デアリング株)
・ PV701、腫瘍溶解性ニューカッスル病ウイルス
・ CG0070、GM−CSFをコードする条件複製アデノウイルス
・ Pexastimogene devacirepvec(Pexa−Vec、JX−594)、GM−CSFをコードするチミジンキナーゼ欠損ワクシニアウイルス
・ Cavatak、未改変コクサッキーウイルスA21
・ Seprehvir(HSV1716)、ICP34.5を欠損している条件複製単純ヘルペス1型
・ DNX−2401、インテグリン結合ペプチドをコードする条件複製アデノウイルス
・ CGTG−102、GM−CSFをコードする条件複製アデノウイルス
単一治療サイクルでサブグループB複製可能な腫瘍溶解性アデノウイルスの非経口製剤の複数回用量を全身投与し、
各投与に与えられる総用量の範囲は、用量当たり1×1010〜1×1014個のウイルス粒子であり、
ウイルスの各用量は、ウイルス粒子の送達速度が、毎分2×1010〜2×1012粒子の範囲にあるように投与される。
a)各用量で投与されるウイルス粒子の数、
b)各ウイルスの用量が投与される速度(毎分に送達されるウイルス粒子の数)
c)治療サイクルにおけるウイルスの個々の用量の数、
d)治療サイクル内のそれぞれ個別の投与の間隔、
e)治療サイクルの間の予防的抗炎症薬の使用、および
f)治療サイクル間の期間。
これらのパラメータは、互いに調整することができ、すなわち投与量が増加している場合は、増加の悪影響をオフセットするために、ゆっくりとした注入速度で投与することができる。
表1は、アデノウイルス血清型の区分を示す。
炎症性壊死性細胞死は、特定の抗腫瘍免疫応答の発生により適切であり得る。
ColoAd1は標的細胞の死より前に、非常に急速に腫瘍細胞を出し、拡散する能力を高めることができる。
より詳細な癌の種類
肺癌は、組織型によって分類され、顕微鏡で、組織病理学者によって見られる悪性細胞の大きさや外観によって分類される。治療目的のために、2つの広いクラスに区別される。1つは非小細胞肺癌であり、もう1つは小細胞肺癌である。
一実施形態では、癌は肝臓癌であり、例えば、原発性癌からの肝転移、例えば肝臓に拡散している結腸癌である。一実施形態では、肝臓癌は肝細胞癌(HCC)である。
一実施形態では、例えば本明細書に開示される腫瘍溶解性アデノウイルスを用いて、腎細胞癌および/または尿路上皮細胞癌といった腎臓癌の治療を提供する。腎臓癌の他の例として、扁平上皮癌、旁糸球体細胞腫(腎腫)、血管筋脂肪腫、腎好酸性顆粒細胞腫、ベリーニ管癌、腎臓の明細胞肉腫、中胚葉性腎腫、ウィルムス腫瘍、混合上皮間質腫瘍、明細胞腺癌、移行上皮癌、反転パピローマ、腎リンパ腫、奇形腫、癌肉腫、および腎盂のカルチノイド腫瘍が挙げられる。
一実施形態では、癌は、膀胱癌であり、例えば、膀胱の上皮層(すなわち、尿路上皮)から生じる悪性腫瘍のいくつかのタイプのいずれかである。膀胱癌の約90%は移行上皮癌である。残りの10%は扁平上皮癌、腺癌、肉腫、小細胞癌および身体の他の部分の癌からの二次堆積物である。ステージングは以下のとおりである。
T(原発腫瘍)
・ TX 原発腫瘍を評価することができない
・ T0 原発腫瘍の証拠がない
・ Ta 非侵襲的な乳頭癌
・ Tis in situの癌腫(「平坦な腫瘍」)
・ T1 腫瘍が上皮下結合組織に浸潤している
・ T2a 腫瘍が表面的な筋肉(内側半分)に浸潤している
・ T2b 腫瘍は奥深くの筋(外側半分)に浸潤している
・ T3 腫瘍が膀胱周囲の組織に浸潤している
・ T3a 微視的
・ T3b 肉眼(膀胱外の質量)
・ T4a 腫瘍が前立腺、子宮または膣に浸潤している
・ T4b 腫瘍が骨盤壁または腹壁に浸潤している
N(リンパ節)
・ NX 所属リンパ節の評価ができない
・ N0 所属リンパ節転移なし
・ N1 最大径が2cm以下の単一リンパ節転移
・ N2 最大径が2cm以上5cm未満の単一のリンパ節、または最大径が5cmより大きくない複数のリンパ節の転移
・ N3 最大径が5cm以上のリンパ節の転移
M(遠隔転移)
・ MX 遠隔転移を評価することができない
・ M0 遠隔転移なし
・ M1 遠隔転移
独立した態様では、本開示はColoAd1に関連し、ColoAd1の製剤またはColoAd1を含む併用療法、卵巣がんを治療する際に使用し、例えば、治療有効量のColoAd1を卵巣がんの患者に投与し、例えば、本明細書に記載の投与計画を使用する。
・ 表面上皮−卵巣の裏層を覆う細胞
・ 生殖細胞−卵を形成するために運命づけられている細胞
・ 間質細胞−ホルモンを放出し、卵巣の異なる構造を接続する細胞
卵巣がんと診断されると、腫瘍のステージは、手術中、癌が卵巣外に広がっているかどうかを医師が見分けることができるときに決定することができる。卵巣がんには4段階ある−ステージI(早期疾患)からステージIV(進行性疾患)。治療計画および予後(疾患のあり得る経過と転帰)が、癌のステージによって決定される。
卵巣がんの様々な段階の説明は次のとおりである。
ステージIA−成長は1つの卵巣に限定され、腫瘍は卵巣の内部に閉じ込められている。卵巣の外表面にがんはない。悪性細胞を含む腹水が全くない。卵巣の被膜はそのままである。
ステージIB−増殖は両方の卵巣に限られ、その外側表面上には腫瘍はない。悪性細胞を含む腹水が全くない。卵巣の被膜はそのままである。
ステージIC−腫瘍は、ステージIAまたはIBのいずれかに分類され、次の一つ以上が存在する、(1)腫瘍が、一方または両方の卵巣の外側表面上に存在する。(2)被膜が破裂している、および(3)悪性細胞を含む腹水または陽性の腹腔洗浄液を伴う腹水がある。
ステージII−骨盤拡張を有する一方または両方の卵巣に癌の成長が見られる。
ステージIIA−癌が子宮や卵管、またはその両方に拡張および/または存在する。
ステージIIB−癌が他の骨盤内の臓器にまで拡張している。
ステージIIC−腫瘍がステージIIAまたはIIBのいずれかに分類され、(1)腫瘍が、一方または両方の卵巣の外側表面上に存在する、(2)被膜が破裂している、および(3)悪性細胞を含む腹水または陽性の腹腔洗浄液を伴う腹水がある、の1つ以上見られる。
ステージIII−一方または両方の卵巣に癌の成長が見られ、(1)癌が骨盤を越えて腹部壁にまで拡散している、(2)癌がリンパ節に拡散している。腫瘍は真の骨盤に限られるが、小腸や大網に、組織学的に証明された悪性の拡張がある。
ステージIIIA−staging operation中、施術者が卵巣の一方または両方を含む癌を見ることがでるが、がんはが腹部の全体に見ることができず、リンパ節に拡散していない。しかし、顕微鏡下で生検チェックを行うと癌の非常に小さな堆積物が腹部の腹膜表面に見られる。
ステージIIIB−腫瘍が一方または両方の卵巣にあり、外科医が確認できるほどに大きいが直径が2cmを超えていない癌の堆積物が存在している。癌はリンパ節に広がっていない。
ステージIIIC−腫瘍が一方または両方の卵巣にあり、(1)癌がリンパ節に拡散している、および/または(2)癌の堆積物の直径が2cmを超えており、腹部に見られる、の一方か両方がある。
ステージIV−最も進行した卵巣癌のステージ。癌の成長は一方または両方の卵巣にあり、および遠隔転移(腹膜腔の外に位置する臓器へ癌が拡散している)が発生している。(肺を取り囲む空洞から)胸水に卵巣癌細胞を見つけることも、ステージIV疾患の証拠になる。
一実施形態では、ウイルスは、癌の治療または療法の投与と組み合わせて投与される。
ナゾリン−5−イル)プロプ−2−インイル)尿素;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−フルオロベンジル)−5−(3−(2−(2−メトキシエトキシ)エトキシ)プロプ−1−インイル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−フルオロ−3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−エチニル−キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(3−フェノキシプロプ−1−インイル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−フルオロベンジル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;6−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(2−メトキシエチル)ヘキス−5−インアミド;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(7−モルホリノ−7−オキソヘプト−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(5−モルホリノ−5−オキソペント−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−((5−メチルピラジン−2−イル)メチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−オキソ−6−(ピペリジン−1−イル)ヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N,N−ジエチルヘキス−5−インアミド;7−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロ−ベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)ヘプト−6−イン酸;2−アセトアミド−N−(3−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)プロプ−2−イン−1−イル)アセトアミド;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(3−メトキシ−5−(トリフルオロメチル)ベンジル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−メトキシフェネチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(ベンゾ[b]チオフェン−2−イルメチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−フルオロ−3−メトキシベンジル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;メチル3−((2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)−4−オキソキナゾリン−3(4H)−イル)メチル)安息香酸;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−((1−メチル−1H−ピラゾール−4−イル)メチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(ベンゾフラン−5−イルメチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−((2−メチルチアゾール−4−イル)メチル)−5−(6−モルホリノ−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(4−メチルピペラジン−1−イル)−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(4−モルホリノピペリジン−1−イル)−6−オキソヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;5−(6−(4−アセチルピペラジン−1−イル)−6−オキソヘキス−1−イン−1−イル)−2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)キナゾリン−4(3H)−オン;N−(4−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)ブト−3−イン−1−イル)モルホリン−4−カルボキサミド;5−(6−(4−アセチル−ピペラジン−1−イル)−6−オキソヘキス−1−イン−1−イル)−2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)キナゾリン−4(3H)−オン;N−(4−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)ブト−3−イン−1−イル)モルホリン−4−カルボキサミド;2−((4−アミノ−3−(4−ヒドロキシ−フェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−5−(5−(ビス(2−メトキシエチル)アミノ)ペント−1−インイル)−3−(2−クロロベンジル)キナゾリン−4(3H)−オン;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−シクロペンチルヘキス−5−インアミド;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(テトラヒドロ−2H−ピラン−4−イル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(2−モルホリノエチル)ヘキス−5−インアミド;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(4−(2−メトキシエチル)ピペラジン−1−イル)−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オン;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(2−(ジメチルアミノ)エチル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(ピリジン−4−イル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(ピリジン−4−イル)ヘキス−5−インアミド;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(4−(ジメチルアミノ)ピペリジン−1−イル)−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オン;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N,N−ビス(2−メトキシエチル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N,N−ビス(2−メトキシエチル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(2−(4−メチルピペラジン−1−イル)エチル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−メチル−N−(2−(4−メチルピペラジン−1−イル)エチル)ヘキス−5−インアミド;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−イソプロピルヘキス−5−インアミド;6−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−イソプロピルヘキス−5−インアミド;6−(2−((4−アミノ−3−(
4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N,N−ジメチルヘキス−5−インアミド;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−オキソ−6−(ピロリジン−1−イル)ヘキス−1−イン−1−イル)キナゾリン−4(3H)−オン;6−(2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N−(ピロリジン−3−イル)ヘキス−5−インアミド;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(3−(ジメチルアミノ)ピロリジン−1−イル)−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(3−(ジメチルアミノ)ピロリジン−1−イル)−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(4−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(4−メチル−1,4−ジアゼパン−1−イル)−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オン;2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−(4−メチル−1,4−ジアゼパン−1−イル)−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オン,2−((4−アミノ−3−(4−ヒドロキシ−3−メトキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−5−(6−モルホリノ−6−オキソヘキス−1−インイル)キナゾリン−4(3H)−オンまたはその立体異性体、互変異性体および同位体誘導体を含むその薬学的に許容される塩が挙げられる。
表2は、様々な上皮細胞株上のColoAd1のIC50を示す。
1 Schering AGによって実施され、Kuhnら,2008に発表された結果。
2 オックスフォード大学(未発表)によって実行された反復と追加の研究。
1 Schering AGによって実施され、Kuhnら,2008に発表された結果。
2 オックスフォード大学(未発表)によって実行された反復と追加の研究。
ColoAd1循環動態をCD−1マウスで得た。マウス(1群当たり3)に尾静脈を介してウィルス粒子を投与し、全血試料中の循環ゲノムを定量的PCR(qPCR)によって測定した。このモデルのColoAd1半減期は用量依存性である。低い入力用量で(複数の投薬日に1×109〜2×1010)、平均アルファ半減期は1.8±0.5分であり、他のアデノウイルス(Green2004)について以前に報告された値と一致する。高用量で(2×1011以上)で、クリアランスの飽和が発生しているように見え、より長い循環レベルが生じる(アルファ半減期7.8±2分を意味する)。本明細書に記載のColoAd1試験の飽和は、複数の薬物動態パラメータを経由して反映される。
表5:CD−1マウス(群あたり3匹のマウス)における複数回の腫瘍内注射の循環動態
ウイルス粒子は、迅速な中和につながる抗体、補体および血液細胞を含む、ヒトの血液の成分と相互作用することができる(Lyons 2005,Carlisle 2009)。これらのイベントは種特異的であり、動物で効果的にモデル化することはできない。
ColoAd1の生体分布およびクリアランスは、正常なマウスおよび一次ウイルス受容体CD46(正常マウスでは発現されないグループBアデノウイルスの受容体)を発現するトランスジェニックマウスにおいて決定した。正常マウスへの1×1011ウイルス粒子の尾静脈投与後、24時間後に肝臓、脾臓および肺にウイルス粒子を優位に見出した。(図2)は、1mg当たりのウイルスコピー数を示し、これらの大きな臓器がパーセンテージに基づき、全ウイルスの分布の主な部位であることを表している。同標的臓器に類似する分布は、CD46トランスジェニックマウス(図3)において観察され、CD46受容体が分布の重要な決定因子ではないことを示した。非複製変異体(ColoAd1CJ132)の分布はColoAd1の分布と同一であり、このことは、複製が当該分布の効果を招いていないことを示している。しかし、ヒトの患者が有する腫瘍では、続く放出で、癌細胞中の当該ウイルスの複製が、後のタイムポイントでのウイルスのさらなる増幅をもたらしていると思われ、そのために臨床試験がそれに応じて計画されたことが予想された。
ウイルスクリアランスが完了するまでの時間を特定するために、長期の粒子クリアランス試験を、正常なBalbcマウスで行った。ウイルス分布に優勢な臓器:肝臓、脾臓および肺を、分析に選択した。ここでは、臓器当たりの全ウイルス粒子を、結果が臓器の重量に対して正規化されないように、各タイムポイントでの投入用量のパーセンテージとして記録する。1時間で、入力ウイルスの大部分は、肝臓内に既に隔離されており、脾臓では5%未満、および肺では0.1%未満隔離されていた。注入後24時間で、ウイルス粒子は急速にこれらの臓器からクリアされ、入力ウィルスゲノムの1%未満が残っていた。注射後65日目を過ぎて、どの組織にも有意なレベルのウイルスは検出されず、レベルは有意にバックグラウンドを超えなかった。投与後65日目に、組織からウイルス粒子を回収することができなかった。ウイルスクリアランスの動態(臓器当たりの入力量の%として提示されたデータ)を図4にまとめる。
特異的な抗ウイルス免疫応答の発生が循環動態に有意な影響を与える可能性がある。この可能性を調べるために、マウスの群に、超免疫血清のプールを生成するために、数ヶ月にわたって繰り返しColoAd1を投与した。マウスの第2の群は、高度免疫血清を使用して、10または20μlの静脈内注射によって投与されるColoAd1に対して受動的に免疫化された。これらのマウスを、その後、10分間休ませ、5×1010ColoAd1静脈内投与した。ColoAd1の投与後2、10、30分で、各マウスから血液を回収し、qPCRにより分析した。結果を図5に示し、ColoAd1に対する免疫応答は、ColoAd1の動態および送達に大きな影響を与えることを示し、したがって、当該応答が起こる前に投与することの重要性を証明している。
いくつかの安全性や毒性研究を、CD−1およびBalb/cマウス、CD46トランスジェニックマウスのパイロット試験を含むColoAd1で実施した。雄および雌のCD−1マウスにおける最後の毒性試験では、ColoAd1を3回の用量として、5日間にわたって投与し(1、3および5日目)、意図される臨床投与計画をモデル化した。雌雄のCD−1マウスに、ColoAd1または表6に示すように、製剤緩衝液を静脈内ボーラス注射(用量体積=100μL)を投与し、第1日目に、2つの群の4匹の雄の予定外の死亡があった後に、特定の群の用量を低くすることになった最終的な試験デザインを示す。
表6:毒性試験デザイン
出願の時点に、転移性癌を有するヒト対象への静脈内送達をしたときのColoAd1の安全性と有効性を調べるために、2つの臨床試験を行った。
表7:ColoAd1−1001臨床試験の第I相用量漸増要素における1〜7コホートのための投与計画。
表8:コホート1〜7のColoAd1薬物動態
nd:測定されず。
図9A:5分かけて投与される1e10(1×1010)ウイルス粒子(コホート1)。図9B:5分かけて投与される1e11(1×1011)ウイルス粒子(コホート2)。図9C:5分かけて投与される1e12(1×1012)ウイルス粒子(コホート3)。図9D:5分かけて投与される1e13(1×1013)ウイルス粒子(コホート4)。図9E:5分かけて投与される3e12(3×1012)ウイルス粒子(コホート5)。図9F:20分かけて投与される3e12(3×1012)ウイルス粒子(コホート6)。図9G:40分かけて投与される6e12(6×1012)ウイルス粒子(コホート7)。
開発中の臨床的に承認された320個の化合物の存在下で、ColoAd1ウイルス複製を結腸癌細胞株HT−29で評価した。HT−29細胞を96ウェルプレート中、ウェルあたり3.0e4細胞の密度で播種し、37℃、5%のCO2でインキュベートした。4〜6時間のインキュベーション後、ウイルスと薬剤化合物の混合物を細胞培地中に調製し、細胞に希釈し、最終用量が細胞あたり10ColoAd1ウイルス粒子(ppc)および0.1μMの薬剤化合物を得た。細胞を18時間インキュベートし、次に、細胞内の全ウイルスゲノムをqPCRにより評価した。単独のColoAd1ウイルスと比較したColoAd1複製の相対倍数変化を、図15個の全化合物についてプロットする。挿入図は、微小管阻害剤の存在下で、18時間後のウイルス複製の増加とトポイソメラーゼ阻害剤の存在下でのウイルス複製の減少を示している。
Claims (27)
- ヒト患者を治療する方法であって、当該方法は以下のステップ:
単一治療サイクルでサブグループBの複製可能な腫瘍溶解性アデノウイルスの非経口製剤の複数回用量を全身投与し、
各投与で与えられる総用量は、用量当たり1×1010〜1×1014ウイルス粒子のの範囲にあり、
ウイルスの各用量は、ウイルス粒子の送達速度が毎分2×1010粒子〜毎分2×1012粒子の範囲にある、を含む方法。 - 各投与で与えられる総用量は用量あたり1×1012〜1×1013ウイルス粒子の範囲にあって、例えば、各投与で与えられる総用量は用量あたり3×1012〜9×1012ウイルス粒子の範囲にあり、特に、各投与で与えられる総用量は用量あたり6×1012ウイルス粒子である、請求項1に記載の方法。
- 各用量投与間の期間は、例えば、48時間等、6〜72時間の範囲にある請求項1または2に記載の方法。
- 複数回用量が単一の治療サイクルで2、3、4、5、6または7回の用量である、請求項1〜3のいずれか一項に記載の方法。
- 治療サイクルは7日または5日等の14日以下の期間である、請求項1〜4のいずれか一項に記載の方法。
- ウイルスの各用量は、ウイルス粒子の送達速度が毎分1×1011ウイルス粒子〜毎分3×1011ウイルス粒子の範囲にあって、例えば、用量あたり、毎分2×1011ウイルス粒子または毎分1.67×1011ウイルス粒子であり、特にウイルス粒子の送達速度が毎分、用量あたり1.5×1011ウイルス粒子であるように各用量のウイルスが投与される、請求項1〜5のいずれか一項に記載の方法。
- 用量当たり1×1013ウイルス粒子が60分かけて投与され、または用量あたり6×1012ウイルス粒子が40分かけて投与される、請求項1〜6のいずれか一項に記載の方法。
- 第2および任意のその後の用量の投与後のウイルスの血漿レベルが、mLあたり少なくとも2×106ウイルス粒子に達する、請求項1〜7のいずれか一項に記載の方法。
- ウイルス粒子の血漿レベルが、例えば20、30、40、50または60分間、15分以上維持される、請求項8に記載の方法。
- 投与される製剤の量が、100mL以下、例えば、約3mLまたは5mL等の30mL以下である、請求項1〜9のいずれか一項に記載の方法。
- 第1の用量は第1日目に投与され、その後、1日おきにさらなる治療用量が投与され、例えば、第1の用量は第1日目に投与され、さらなる治療用量が第3または5日目に投与される、請求項1〜10のいずれか一項に記載の方法。
- アデノウイルスはキメラアデノウイルスであり、例えば、キメラアデノウイルスはColoAd1である、請求項1〜11のいずれか一項に記載の方法。
- 請求項1〜12のいずれか一項に記載の方法であって、ウイルスを、化学療法剤を含むその他の抗癌剤、その抗体またはその断片等の免疫療法剤、キナーゼ阻害剤またはmTOR阻害剤等の小分子阻害剤、放射線療法、放射性同位元素療法またはそれらの任意の組み合わせと併用して投与する、方法。
- ウイルスを、例えば、解熱剤、制吐剤、ステロイドおよび鎮痛剤から選択される1種以上の予防剤の投与と併用して投与する、請求項1〜13のいずれか一項に記載の方法。
- 結腸直腸の悪性腫瘍等、例えば固形腫瘍といった腫瘍の治療のための請求項1〜14のいずれか一項に記載の方法。
- 第1および治療用量が109〜1014ウイルス粒子の範囲にある請求項1〜23いずれか一項に記載の方法。
- アデノウイルスが少なくとも部分的に患者の免疫系を回避するように処方される、請求項1〜16のいずれか一項に記載の方法。
- アデノウイルスは導入遺伝子を含む、請求項1〜17のいずれか一項に記載の方法。
- 治療によって血漿サイトカインレベルの増加を伴う癌細胞の壊死につながる、請求項1〜17のいずれか一項に記載の方法。
- 前記患者に静脈内投与を行う工程を含むColoAd1を含む医薬製剤で患者を治療する方法であって、
第1日目に第1の治療用量、次に
第3日目に第2の治療用量および
第5日目に第3の治療用量、を投与する方法。 - ヒト患者を治療する方法であって、当該方法は、単一治療サイクルにおいて、サブグループB複製可能な腫瘍溶解性アデノウイルスを複数回、全身投与し、各投与に与えられる総用量の範囲は1×1010〜1×1013ウイルス粒子であり、1分〜90分かけて投与され、例えば、各投与で与えられる総用量の範囲は6×1012ウイルス粒子であり、40分かけて投与される、方法。
- 各投与に与えられる総用量の範囲は1×1010〜1×1014または1×1010〜1×1013ウイルス粒子であり、1〜90分かけて投与される、単一治療サイクルでアデノウイルスを含む非経口製剤を複数回、全身投与することによって、ヒト患者を治療するのに使用されるサブグループB複製可能な腫瘍溶解性アデノウイルス。
- 粒子の送達速度が毎分2×1010粒子〜毎分2×1012の範囲にあるように、総投与用量は用量あたり1×1010〜1×1014ウイルス粒子の範囲にある、請求項22に記載の使用のためのサブグループB複製可能な腫瘍溶解性アデノウイルスの非経口製剤。
- 単一治療サイクルでアデノウイルスを含む非経口製剤を、複数回用量を全身投与することによって、ヒト患者の治療に使用される医薬物使用の製造のためのサブグループB複製可能な腫瘍溶解性アデノウイルスの使用であって、各投与に与えられる総用量が1×1010〜6×1012ウイルス粒子の範囲にあり、1分〜90分かけて投与される、使用。
- 3〜50mlの範囲の内部容積を有するガラスまたはプラスチック製注射器の使用であって、当該注射器は、サブグループB複製可能腫瘍崩壊アデノウイルスを1×1010〜6×1012ウイルス粒子を含む非経口製剤を含み、製剤は無菌であり、例えば、請求項1〜21のいずれか一項に従って、治療に使用するために、特に、ヒト対象に注射または静脈内注入が可能な薬剤の製造に使用するために、無菌状態下で充填される、使用。
- 例えば、本明細書に記載の投与計画を用いて、治療効果量のColoAd1を卵巣癌の患者に投与する、卵巣癌の治療に使用するColoAd1。
- ColoAd1等のB型アデノウイルス、およびin vivoでのウイルス複製等、アデノウイルスの活性を阻害しない化学療法剤を含む併用療法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1310698.4 | 2013-06-14 | ||
GB201310698A GB201310698D0 (en) | 2013-06-14 | 2013-06-14 | Method |
GB1405140.3 | 2014-03-22 | ||
GB201405140A GB201405140D0 (en) | 2014-03-22 | 2014-03-22 | Method |
GB1406509.8 | 2014-04-10 | ||
GB201406509A GB201406509D0 (en) | 2014-04-10 | 2014-04-10 | Method |
PCT/EP2014/062284 WO2014198852A2 (en) | 2013-06-14 | 2014-06-12 | A dosing regime and formulations for type b adenoviruses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020151615A Division JP2020203932A (ja) | 2013-06-14 | 2020-09-09 | B型アデノウイルスのための投与計画および製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016526531A true JP2016526531A (ja) | 2016-09-05 |
JP2016526531A5 JP2016526531A5 (ja) | 2016-10-20 |
JP6797680B2 JP6797680B2 (ja) | 2020-12-16 |
Family
ID=51162703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016518498A Active JP6797680B2 (ja) | 2013-06-14 | 2014-06-12 | B型アデノウイルスのための投与計画および製剤 |
JP2020151615A Pending JP2020203932A (ja) | 2013-06-14 | 2020-09-09 | B型アデノウイルスのための投与計画および製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020151615A Pending JP2020203932A (ja) | 2013-06-14 | 2020-09-09 | B型アデノウイルスのための投与計画および製剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US11173186B2 (ja) |
EP (2) | EP3007711B1 (ja) |
JP (2) | JP6797680B2 (ja) |
KR (3) | KR20160026970A (ja) |
CN (2) | CN105431157A (ja) |
AU (2) | AU2014280123B2 (ja) |
BR (1) | BR112015030881A2 (ja) |
CA (2) | CA3176971A1 (ja) |
HK (1) | HK1223564A1 (ja) |
IL (1) | IL243071B (ja) |
RU (1) | RU2671558C2 (ja) |
SG (1) | SG11201510064WA (ja) |
WO (1) | WO2014198852A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018182014A1 (ja) * | 2017-03-31 | 2018-10-04 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
WO2019189643A1 (ja) * | 2018-03-30 | 2019-10-03 | 国立大学法人東京大学 | 腫脹発生抑制型腫瘍溶解性ウイルス |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
WO2021067310A1 (en) * | 2019-09-30 | 2021-04-08 | Candel Therapeutics, Inc. | Combination gmci and atri cancer treatment |
CN114469938A (zh) * | 2020-10-27 | 2022-05-13 | 中国医学科学院药物研究所 | 化合物bix02189在制备抗流感病毒药物中的应用 |
CN114601838B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种azd8055在制备用于抗腺病毒感染的药物中的用途 |
WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519175A (ja) * | 1997-10-09 | 2001-10-23 | プロ − バイラス,インコーポレイテッド | ウイルスを用いた新生物の処置 |
JP2008500051A (ja) * | 2004-05-26 | 2008-01-10 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 癌処理への使用のためのキメラアデノウィルス |
JP2010514418A (ja) * | 2006-12-22 | 2010-05-06 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 腫瘍退縮アデノウイルスの作出およびその使用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
EP1137792B9 (en) | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
US7279318B1 (en) | 1999-06-09 | 2007-10-09 | Hybrid Systems Limited | Modification of biological elements |
EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
US20040167088A1 (en) * | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
EP1646717A4 (en) | 2003-07-18 | 2006-12-20 | Onyx Pharma Inc | ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES |
KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 cd3-바인더 |
GB0416487D0 (en) | 2004-07-23 | 2004-08-25 | Isis Innovation | Modified virus |
US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
RU2382884C2 (ru) | 2006-07-10 | 2010-02-27 | Александр Владимирович Дидин | Сферическая объемная роторная машина и способ работы сферической объемной роторной машины |
EP2296678A4 (en) | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION |
MX2011003553A (es) | 2008-10-02 | 2011-05-25 | Respivert Ltd | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38. |
CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
US20110243897A1 (en) | 2008-12-11 | 2011-10-06 | Leonard William Seymour | Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
WO2013074507A2 (en) | 2011-11-14 | 2013-05-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
SG11201602887QA (en) | 2013-10-25 | 2016-05-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
KR20170044194A (ko) | 2014-08-27 | 2017-04-24 | 싸이오서스 테라퓨틱스 엘티디. | 아데노바이러스의 제조를 위한 공정 |
-
2014
- 2014-06-12 AU AU2014280123A patent/AU2014280123B2/en active Active
- 2014-06-12 CA CA3176971A patent/CA3176971A1/en active Pending
- 2014-06-12 KR KR1020167000214A patent/KR20160026970A/ko active Application Filing
- 2014-06-12 JP JP2016518498A patent/JP6797680B2/ja active Active
- 2014-06-12 RU RU2015152860A patent/RU2671558C2/ru active
- 2014-06-12 KR KR1020217013679A patent/KR20210054067A/ko not_active Application Discontinuation
- 2014-06-12 EP EP14736650.4A patent/EP3007711B1/en active Active
- 2014-06-12 WO PCT/EP2014/062284 patent/WO2014198852A2/en active Application Filing
- 2014-06-12 CN CN201480033427.XA patent/CN105431157A/zh active Pending
- 2014-06-12 KR KR1020217041147A patent/KR20210156857A/ko not_active Application Discontinuation
- 2014-06-12 EP EP20198714.6A patent/EP3777870A1/en active Pending
- 2014-06-12 CN CN202011432713.7A patent/CN112516179A/zh active Pending
- 2014-06-12 SG SG11201510064WA patent/SG11201510064WA/en unknown
- 2014-06-12 BR BR112015030881A patent/BR112015030881A2/pt not_active Application Discontinuation
- 2014-06-12 CA CA2914790A patent/CA2914790C/en active Active
- 2014-06-12 US US14/896,294 patent/US11173186B2/en active Active
-
2015
- 2015-12-09 IL IL24307115A patent/IL243071B/en active IP Right Revival
-
2016
- 2016-10-17 HK HK16111964.1A patent/HK1223564A1/zh unknown
-
2020
- 2020-02-14 AU AU2020201101A patent/AU2020201101B2/en active Active
- 2020-09-09 JP JP2020151615A patent/JP2020203932A/ja active Pending
-
2021
- 2021-09-23 US US17/448,549 patent/US20220054563A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519175A (ja) * | 1997-10-09 | 2001-10-23 | プロ − バイラス,インコーポレイテッド | ウイルスを用いた新生物の処置 |
JP2008500051A (ja) * | 2004-05-26 | 2008-01-10 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 癌処理への使用のためのキメラアデノウィルス |
JP2010514418A (ja) * | 2006-12-22 | 2010-05-06 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 腫瘍退縮アデノウイルスの作出およびその使用 |
Non-Patent Citations (5)
Title |
---|
GENE THER., vol. 21, JPN6019027556, February 2014 (2014-02-01), pages 440 - 443, ISSN: 0004076881 * |
HUM. GENE THER., vol. 23, no. 10, JPN5016006922, 2012, pages 19, ISSN: 0004076877 * |
PLOS ONE, vol. 3, JPN6018005475, 2008, pages 1 - 9, ISSN: 0004076878 * |
PLOS ONE, vol. Vol.3 Iss.6, JPN6019027555, 2008, pages 2409, ISSN: 0004076879 * |
実験動物の被験物質の投与(投与経路、投与容量)及び採血に関する手引き, JPN6019027557, 2000, ISSN: 0004076880 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018182014A1 (ja) * | 2017-03-31 | 2018-10-04 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
JPWO2018182014A1 (ja) * | 2017-03-31 | 2020-02-20 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
JP7114571B2 (ja) | 2017-03-31 | 2022-08-08 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
US11857584B2 (en) | 2017-03-31 | 2024-01-02 | Hisanobu OGATA | Oncolytic virus growth method and antitumor agent |
WO2019189643A1 (ja) * | 2018-03-30 | 2019-10-03 | 国立大学法人東京大学 | 腫脹発生抑制型腫瘍溶解性ウイルス |
JPWO2019189643A1 (ja) * | 2018-03-30 | 2021-04-01 | 具紀 藤堂 | 腫脹発生抑制型腫瘍溶解性ウイルス |
JP7429046B2 (ja) | 2018-03-30 | 2024-02-07 | 具紀 藤堂 | 腫脹発生抑制型腫瘍溶解性ウイルス |
Also Published As
Publication number | Publication date |
---|---|
CA2914790A1 (en) | 2014-12-18 |
AU2014280123B2 (en) | 2019-11-14 |
SG11201510064WA (en) | 2016-01-28 |
AU2020201101A1 (en) | 2020-03-05 |
HK1223564A1 (zh) | 2017-08-04 |
US20160120922A1 (en) | 2016-05-05 |
WO2014198852A3 (en) | 2015-04-02 |
IL243071B (en) | 2019-10-31 |
RU2671558C2 (ru) | 2018-11-02 |
CN105431157A (zh) | 2016-03-23 |
EP3777870A1 (en) | 2021-02-17 |
RU2015152860A (ru) | 2017-07-19 |
CA3176971A1 (en) | 2014-12-18 |
EP3007711A2 (en) | 2016-04-20 |
US11173186B2 (en) | 2021-11-16 |
KR20210054067A (ko) | 2021-05-12 |
RU2015152860A3 (ja) | 2018-05-04 |
EP3007711B1 (en) | 2020-10-21 |
JP2020203932A (ja) | 2020-12-24 |
WO2014198852A2 (en) | 2014-12-18 |
AU2020201101B2 (en) | 2021-10-21 |
JP6797680B2 (ja) | 2020-12-16 |
CA2914790C (en) | 2024-02-27 |
KR20160026970A (ko) | 2016-03-09 |
CN112516179A (zh) | 2021-03-19 |
KR20210156857A (ko) | 2021-12-27 |
BR112015030881A2 (pt) | 2017-10-24 |
US20220054563A1 (en) | 2022-02-24 |
AU2014280123A1 (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220054563A1 (en) | Dosing regime and formulations for type b adenoviruses | |
US12090183B2 (en) | Methods of treating solid or lymphatic tumors by combination therapy | |
US20220125864A1 (en) | Methods of treating solid or lymphatic tumors by combination therapy | |
Levitzki et al. | Signal transduction therapy of cancer | |
WO2017013421A1 (en) | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood | |
JP2014502970A (ja) | 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成 | |
WO2022111618A1 (zh) | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 | |
Omay et al. | Current concepts and newer developments in the treatment of malignant gliomas | |
Cao et al. | Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: three birds with one stone | |
JP2023549698A (ja) | がんの治療のためのナノ粒子の組成物 | |
WO2016097158A1 (en) | Method of treating ovarian cancer | |
WO2023174278A1 (zh) | 抗tim-3抗体与去甲基化药物的药物组合 | |
Guinn et al. | 8th international conference on oncolytic virus therapeutics | |
Younis et al. | Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine | |
Kuczynski | Mechanisms of reversible sorafenib resistance in hepatocellular carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160112 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160713 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180521 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190312 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190312 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20190402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190329 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190508 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190513 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190719 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190725 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200110 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200410 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200609 |
|
C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200909 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20201002 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20201029 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20201029 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6797680 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |